Under the terms of the agreement, Precision will use MaxCyte's flow electroporation cell engineering technology alongside its own ARCUS genome-editing platform.
The plan is to develop the next generation of cell-based therapies for cancer.
"Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems,” said its chief development officer David Thomson.
“In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximising overall yield."
Building on earlier deal
The new tie-up builds on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.
"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said MaxCyte chief executive Doug Doerfler.
The AIM-listed life sciences group’s flow electroporation technology allows cells to be re-engineered efficiently, with high viability and recovery.
Precision will use its ARCUS gene editing tools and the MaxCyte’s breakthrough to transform donor cells into immunotherapies such CAR-T cells.